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Abstract 
Problem: The National Institute for Mental Health (NIMH) reports that only 1.2% 
of adults suffer from OCD, but over 50% are severe (Obsessive Compulsive 
Disorder (OCD), n.d.).  Meier et al. (2016), found that patients with OCD faced a 
40% higher chance of early mortality.  Individuals with psychiatric conditions are 
more at risk for poor physical health, poor education, economic struggles and 
crime (Mental Health by the Numbers, 2019).  Emergency departments claim 
tens of millions of visits per year related to psychiatric issues resulting in billions 
in costs each year (Mental Health by the Numbers, 2019).  Genetic testing is 
becoming a more frequently used tool in the battle against mental illness, but it 
can be expensive and its value in improving clinical outcomes is still up for 
debate (What is the cost of genetic testing, n.d.).   
Methods: A descriptive, observational, quality improvement project aimed at 
evaluating clinical outcomes among genetically tested patients with OCD. 
Results:  This quality improvement project included 15 patients (n=15), 6 who 
were genetically tested (n=6, 40%) and 9 who were not (n=9, 60%). An analysis 
of variance (ANOVA) was conducted based on an alpha value of 0.05 for each 
clinical outcome and all were insignificant.  
Implications for practice:  Providers and Patients should seriously consider the 
cost before utilizing routine genetic testing in patients with OCD.  A larger 
sample size should be used in future studies.  
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Evaluating the Effects of Genetic Testing on  
Patients with Obsessive Compulsive Disorder 
Mental health conditions pose a serious burden in the US. The National 
Alliance for Mental Health reports that 1 in 5 adults face mental health issues 
each year (Mental Health by the Numbers, 2019). In 2017, that represented over 
46 million individuals (Mental Illness, n.d.). When looking at obsessive 
compulsive disorder (OCD) specifically, the National Institute for Mental Health 
(NIMH) reports that while only 1.2% of adults suffer from OCD, over 50% of 
those have impairment that is deemed “severe” (Obsessive Compulsive Disorder 
(OCD), n.d.). A Danish study in 2016 by Meier et al., found that even after 
accounting for associated disorders and substance abuse, patients with OCD 
faced a 40% higher chance of early mortality compared to the general 
population. Genetic testing is becoming a more frequently used tool in the battle 
against mental illness, but it can cost anywhere between $100-$2000 and its 
value in improving clinical outcomes is still up for debate (What is the cost of 
genetic testing, n.d.). This project will seek to answer the study question: What 
effect does genetic testing have on clinical outcomes such as medication 
changes, side effects, tolerance and therapeutic response in patients aged 18-60 
being treated for OCD compared to those who only undergo traditional clinical 
assessment and management? 
According to the NIMH, OCD affects women more than men and young 
adults show the highest incidence (Obsessive Compulsive Disorder (OCD), n.d.). 
The second leading cause of death in individuals ages 10 to 34 is suicide (Mental 
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Health by the Numbers, 2019). Individuals who struggle with psychiatric 
conditions are more at risk for deterioration of physical health as well as issues 
with poor education, economic struggles and crime (Mental Health by the 
Numbers, 2019). Emergency departments claim 10’s of millions of visits per year 
related to psychiatric issues resulting in billions of dollars in treatment costs each 
year (Mental Health by the Numbers, 2019).     
Treating mental health diagnoses is complex with unique challenges. 
Treatment is often an emotional roller-coaster as the hope of a new drug is often 
followed by disappointment when, after weeks of waiting, it proves ineffective or 
intolerable. This cycle can be repetitive resulting in despair, hopelessness and 
ultimately defeat leading patients to cease treatment rather than face another 
painful cycle. In addition, potentially life altering side effects may occur with many 
mental health medications leading patients to struggle with treatment adherence. 
Genetic testing may offer a potential “short cut” by identifying a patient’s 
specific genetic variations allowing the provider to select the most effective and 
least disruptive medication for that specific patient much sooner, reducing 
treatment failure and non-adherence. For example, Smits et al. (2007) showed 
that among patients with depression, up to 40% will be resistant to SSRI’s, the 
current first line treatment, due to genetic variations related to Serotonin 
processing. Using that information in treatment selection for patients with major 
depression increased the 6-week remission rate by almost 5% (Smits et al., 
2007).   
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Current practices at a psychiatric outpatient clinic in a large mid-western 
city vary widely from provider to provider. The clinic has been utilizing the 
Genomind test for approximately two years. Some providers are highly motivated 
to use the test to guide their treatment plan, while others are unsure of the value 
of testing and prefer to rely on traditional clinical assessment alone. Some tests 
are reserved for highly treatment resistant patients, while others are targeted 
towards specific diagnoses. Patient input is often a determining factor as some 
patients are resistant to offering up their DNA while others simply “want to know”.  
For some patients, finding that their genetics explain why they are struggling is 
confirming and helpful in coming to terms with their condition. The findings of this 
quality improvement project may help to guide future practice. 
Review of Literature 
This project began with a review of the current literature as it pertained to 
the topic of the effectiveness of genetic testing in mental health, anxiety and 
OCD. The databases of PubMed, CINAHL and Google Scholar were searched 
for articles using various combinations of the terms mental health, behavioral 
health, psych*, effectiveness, anxiety, OCD, clinical outcomes, side effects, 
therapeutic response, medication changes, genetic and genomic testing. Articles 
were limited to having been published between January 1st, 2015 and the 
present.  
Three articles discussed the basics of genetic testing and its role in 
anxiety disorders. McGowan (2019) explains the current status of studies relating 
to anxiety and genetic testing and provides evidence that multiple gene variants 
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could account for variations of severity of disease as well as response to 
medications. Tomasi et al. (2019) also discussed current knowledge of specific 
genetic variants as they pertained to anxiety disorders. Both articles emphasize 
the serotonin system. Smoller (2015) elaborates on what is and isn’t known 
regarding the role of genetic variants in these disorders. All three articles discuss 
the complexity of the anxiety family of disorders and inconsistencies among 
current knowledge and acknowledge that while there are known genetic markers 
of interest, there is much room for further study specific to anxiety disorders. 
One study, by Perlis et al., (2018), focused on cost effectiveness of 
genetic testing for anxiety patients, as the test can be as high as $2000 (What is 
the cost of genetic testing, n.d.). After comparing health claims between anxiety 
patients who received genetic testing to those who had not, it was determined 
that the tested group had statistically significant reductions in emergency room 
visits and hospitalizations resulting in an estimated savings of almost $2,000 over 
the 6 months (Perlis et. al, 2018). This potential savings could help justify the 
cost. 
Three articles focused on the overall utility of genetic testing in anxiety 
disorder patients. A 2017 article by Tiwari et al. analyzed the Individualized 
Medicine: Pharmacogenetic Assessment and Clinical Treatment (IMPACT) study 
and the MEDCO dataset to evaluate the effectiveness of genetic testing. It was 
determined that there were statistically significant reductions of symptoms and 
benzodiazepine usage post genetic testing. Bradley et al., (2017) found 
statistically significant improvement in outcomes among patients with depression 
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and anxiety whose treatment was based on genetic testing when compared to 
the untested groups. The 2018 systematic review by Solomon, Cates and Li 
(2019) examined 16 studies between 2013 and 2018. While data was 
inconsistent, it was inferred that testing may benefit the population even though it 
may not necessarily equate to improved outcomes. Further research was 
recommended to determine whether the use of genetic testing translates to 
actual improvement in clinical outcomes.  
A deeper review of the literature specifically regarding genetic testing as it 
pertains to OCD revealed 4 additional articles. Song et al. (2017) found that 
mutations within the SLITRK5 gene were implicated in OCD in both mice and 
humans. Other articles spoke to the role of neurotransmitters and their 
involvement in patient response to selective serotonin reuptake inhibitors 
(SSRIs). Sina, Ahmadiani, Asagi and Shams (2018) found a link between HTR2A 
haplotypes and therapeutic response to fluvoxamine in patients with OCD.  
Contrarily, Gomes et al. (2018) was unable to find a correlation with OCD and 
HTR2A but did find strong associations with OCD and the polymorphism in 
SLC6A4 STin2, another gene involved in serotonin transportation. Umehara et al. 
(2016) identified the calcium signaling pathway as being associated with 
therapeutic response to both SSRIs and SSRIs combined with antipsychotics.  
In summary, genetic markers and variants among individuals can play a 
role in the presentation of anxiety and OCD as well as the response to 
medication therapy. Evidence has shown various benefits of genetic testing in 
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reducing medication costs and usage. There is insufficient data regarding 
improvement in clinical outcomes among genetically tested patients.     
Method 
Design 
 This project was a descriptive, observational, quality improvement project 
aimed at evaluating the clinical outcomes of prescribed medication changes, side 
effects, medication tolerance and therapeutic response among genetically tested 
patients with OCD compared to OCD patients who are not tested. 
Framework 
 This project followed a Plan-Do-Study-Act (PDSA) framework. Each step 
is discussed further in the subsequent sections. This project evaluated the effects 
of genetic testing on clinical outcomes among patients with OCD. To execute this 
the researcher compared a convenience sample of OCD patients whose 
treatment was based on genetic testing to a convenience sample of OCD 
patients whose treatment was based only on traditional clinical diagnosis and 
assessment. A retrospective chart review of a 6-month period was used to 
evaluate each group and the effects of genetic testing on the clinical outcomes of 
medication changes, side effects, tolerance of medications and therapeutic 
response compared between the two groups.  
Setting 
 This project took place in an outpatient psychiatric care clinic in a large 
mid-western city. The practice employs one physician and four nurse 
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practitioners and treats both pediatric and adult patients with all types of mental 
health conditions, including substance abuse.  
Sample 
   In addition to obtaining the necessary approvals, the planning of the 
sample process was included in the Plan portion of the PDSA. The sample was a 
convenience sample of patients meeting the inclusion/exclusion criteria.  
Included for study were patients aged 18-60, seeking treatment for OCD whose 
initial visit and/or initial genetic test fell within the 12-month window between 
January 1st and December 31st of 2019. Excluded from the study were any 
patients exhibiting suicidal thoughts or intent, those with concurrent diagnoses of 
any personality disorders, those who were not actively being treated for OCD or 
related complications, and any patients who did not continue care for at least 6 
months following initiation of treatment. These were divided into two groups: 
patients who received genetic testing within that time frame and patients who did 
not. 
Data Collection 
Data collection made up the Do section of the PDSA framework. Following 
clinic and IRB approval, read-only access to the medical records was obtained 
from the clinic. Data was collected via retrospective chart review. Data collected 
included patient demographics divided categorically to protect patient identities, 
initial anxiety scores based on the Patient Health Questionnaire (PHQ-9) and 
initial treatment recommendations among both groups. Data collected at three 
and six months included genetic markers/variants found, subsequent PHQ-9 
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scores, level of therapeutic response to initial recommended therapy (ie. no 
response, sub-therapeutic, therapeutic), side effects experienced (divided by 
category type), whether or not the side effects were tolerable, and number of 
medication changes. All data was collected and organized using a Word 
document collection tool (Appendix A) and then entered into Intellectus Statistics 
for analysis. All data was de-identified, coded and protected for patient privacy.  
Names were removed, and ages were coded by broad categories rather than 
actual age (ie. 18-24, 25-34, etc.). While genetic markers and variants found via 
testing were listed, these are found in all humans, making it impossible to utilize 
this data to track back to any single individual. All paper collection tools were 
stored in a locked filing cabinet and all records were accessed via a single, 
password protected laptop, both accessible to the researcher alone. Data will be 
secured in the same manner for 5 years, after-which it will be deleted or 
shredded utilizing the clinic’s professional shredding service.  
Data Analysis 
 Data Analysis made up the Study portion of PDSA. Data was analyzed 
using Intellectus Statistics. Descriptive data such as mean age group, gender, 
etc., was extrapolated on both groups to summarize the samples. ANOVA was 
utilized to compare the control group of patients receiving traditional clinical 
assessment-based care to OCD patients who received care guided by genetic 
testing to evaluate whether or not the genetic group showed significant changes 
in the identified clinical outcomes. These changes may have included greater 
reduction of PHQ9 scores, higher level or sooner reaching of therapeutic 
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response, less or more tolerable side effects, or less changes to medications. 
The Act portion of PDSA included any recommendations to the clinic in terms of 
how they utilize genetic testing which can be made based on the findings of this 
project. 
Approval Process 
An integral part of the Plan of PDSA, organizational approval was 
obtained after an in-person verbal proposal presentation given to all providers 
and clinic staff at the clinic’s weekly provider meeting. Committee approval 
through UMSL was obtained after project proposal defense. UMSL IRB approval 
was received.  
Results 
A retrospective chart review of the clinic’s patients who met criteria 
resulted in a total of 15 patients (n=15), 6 who were genetically tested (n=6, 40%) 
and 9 who were not (n=9, 60%). 100% (n=15) of the patients selected were 
female. The most frequently observed categories of age were 18-24 and 25-34, 
each with an observed frequency of 5 (33%).   
GRIK1 is the glutamate receptor and is highly associated with anxiety 
disorders such as OCD (Terbeck, Akkus, Chesterman, & Hasler, 2015.). It can 
present as A/A, A/C, or C/C and the C allele is associated with alcohol addiction.  
C allele carriers have shown good response to Topiramate when compared with 
Placebo (Selfdecode, n.d.). When examining the genetic variants among the 
tested patients, the most frequently observed category of Grik1 was A/C (n = 3, 
50%).  
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ANK3 is involved in the production of homocysteine and variations of this 
gene may be associated with methylenetetrahydrofolate reductase deficiency. It 
can present as C/C, C/T, or T/T and the presence of the T allele is associated 
with bipolar disorder and attention deficits (Genecards, n.d.). The most frequently 
observed category of ANK3 was C/C, or normal (n = 6, 100%).   
CACNA1c is a gene involved in producing calcium channels and may be 
associating with learning and rewards processing and can present as A/A, A/G or 
G/G and the presence of an A allele is associated with bipolar disorder 
(Genecards, n.d). The most frequently observed category of CACNA1c was G/G 
(n = 5, 83.3%).  
SL64A is a sodium-dependant transporter gene involved in the movement 
of serotonin between synapses (PubChem, n.d.). It has multiple alleles and can 
present as La/La, Lg/Lg, L/S, or S/S with the S allele being highly associated with 
depression. The most frequently observed category of SL64A was L/S (n = 4, 
66.67%).  
COMT is an enzyme that helps break down neurotransmitters in the pre-
frontal cortex such as epinephrine and dopamine (Selfdecode, n.d.). It may 
present as Val/Val, which have high levels of COMT activity resulting in lower 
dopamine levels, Met/Val or Met/Met which has the lowest levels of activity and 
therefor higher levels of dopamine (GeneCards, n.d.). The most frequently 
observed category of COMT was Met/Val, or normal (n = 4, 66.67%).  
Frequencies and percentages are presented in Table 1. 
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An analysis of variance (ANOVA) was conducted based on an alpha value 
of 0.05 for each clinical outcome to determine whether there were significant 
differences between the genetically tested group and the non-tested group. 
For medication changes at 3 months, the results of the ANOVA were not 
significant, F(1, 13) = 1.62, p = .226. For number of medication changes at 6 
months, the results of the ANOVA were not significant, F(1, 13) = 0.01, p 
= .909. ). The means and standard deviations are presented in Table 2 and Table 
3, and can be visualized in Figure 1.  
For medication tolerance at 3 months, the results of the ANOVA were not 
significant, F(1, 13) = 0.00, p = 1.000. For therapeutic response at 3 months, the 
results of the ANOVA were not significant, F(1, 13) = 1.56, p = .234. For side 
effects at 3 months, the results of the ANOVA were not significant, F(1, 13) = 
0.24, p = .635. These findings indicated there were no significant differences in 
clinical outcomes at 3 months between the genetically tested group and the non-
tested group (Table 2). The percentages and standard deviations are presented 
in Table 2.  
  For medication tolerance at 6 months, the results of the ANOVA were not 
significant, F(1, 13) = 1.56, p = .234. For therapeutic response at 6 months, the 
results of the ANOVA were not significant, F(1, 13) = 0.04, p = .847.  For side 
effects at 6 months, the results of the ANOVA were not significant, F(1, 13) = 
0.01, p = .939. These findings indicated there were no significant differences in 
clinical outcomes at 6 months between the genetically tested group and the non-
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tested (Table 3). The percentages and standard deviations are presented in 
Table 3 and can be visualized in Figure 2. 
An analysis of variance (ANOVA) was also conducted to determine 
whether there were significant differences in PHQ9 scores over time by genetic 
testing. 
The ANOVA was examined based on an alpha value of 0.05. The results 
of the ANOVA were not significant, F(1, 13) = 0.13, p = .720, indicating the 
differences in change for the PHQ9 scores from initial to 6 months between the 
genetically tested group and the non-tested group were similar and not significant 
(Table 4). The means and standard deviations are presented in Table 5. 
Discussion 
 Genetic testing is becoming increasingly available to providers and 
patients to aid in guiding treatment for mental health conditions. While the 
literature suggests that genetic testing may offer many insights into the 
functioning of various systems as they relate to mental health disorders, this 
quality improvement project aimed to see if testing translated to improved clinical 
outcomes. No significant differences in clinical outcomes were found among the 
genetically tested group compared to the group that was treated with traditional 
diagnosis and management. Of note, all variables showed considerably better 
outcomes at the 6 months compared to at 3 months, regardless of testing group 
suggesting that effective treatment of mental health takes time, persistence, and 
patience.   
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Upon reflection, several factors may have contributed to the lack of 
statistical significance. Despite reviewing one year of patients seen, the sample 
size was very small. This was due to the researcher’s efforts to find the most 
accurate, homogenous sample. The study did not account for practice 
differences among the five providers and differences in how they utilize the 
genetic findings in their treatment plans. Finally, the PHQ9 screening tool, while 
helpful in gauging generalized data on patient progress with depression, may not 
have been the most accurate tool in reflecting progress with OCD symptoms.  
Conclusion 
 This quality improvement project did not find evidence to suggest that 
clinical outcomes are improved after genetic testing. Recommendations for future 
practice would include discouraging routine genetic testing for OCD patients as 
traditional diagnosis and management showed similar clinical outcomes 
compared to the genetically tested group in this project. Any discussion regarding 
genetic testing should be done thoughtfully between patient and provider when 
considering treatment options. Given the potentially high cost of genetic testing to 
patients and the healthcare system as a whole, providers should take great care 
before choosing to utilize genetic testing in this patient population. Future studies 
evaluating clinical outcomes as they relate to genetic testing in patients with OCD 
should consider utilizing a larger sample size, controlling for practice methods by 
focusing on a single provider and utilizing a screening tool specific for OCD. 
 
 
Running Head: EFFECTS OF GENETIC TESTING 16 
 
References 
Bradley, P., Shiekh, M., Mehra, V., Vrbicky, K., Layle, S., Olson, M. C., . . . 
Lukowiak, A. A. (2018). Improved efficacy with targeted pharmacogenetic-
guided treatment of patients with depression and anxiety: A randomized 
clinical trial demonstrating clinical utility. Journal of Psychiatric Research, 
96, 100-107. doi:10.1016/j.jpsychires.2017.09.024 
GeneCards(n.d.). ANK3 gene. Retrieved from https://www.genecards.org/cgi-
bin/carddisp.pl?gene=ANK3 
GeneCards(n.d.). CACNA1C gene. Retrieved from 
https://www.genecards.org/cgi-
bin/carddisp.pl?gene=CACNA1C&keywords=cacna1c 
GeneCards(n.d.). COMT. Retrieved from https://www.genecards.org/cgi-
bin/carddisp.pl?gene=COMT&keywords=COMT 
Gomes, C. K., Vieira-Fonseca, T., Melo-Felippe, F. B., Andrade, J. B., 
Fontenelle, L. F., & Kohlrausch, F. B. (2018). Corrigendum to “Association 
analysis of slc6a4 and htr2a genes with obsessive-compulsive disorder: 
Influence of the stin2 polymorphism” [COMPR. Psychiatry 82 (2018) 1–6]. 
Comprehensive Psychiatry, 86, 144. doi:10.1016/j.comppsych.2018.08.005 
Intellectus Statistics. (2019). Intellectus Statistics [Online computer software]. 
Retrieved from http://analyze.intellectusstatistics.com/ 
Mcgowan, O. (2020). Pharmacogenetics of anxiety disorders. Neuroscience 
Letters, 726, 134443. doi:10.1016/j.neulet.2019.134443 
Running Head: EFFECTS OF GENETIC TESTING 17 
 
Meier, S. M., Mattheisen, M., Mors, O., Schendel, D. E., Mortensen, P. B., & 
Plessen, K. J. (2016). Mortality among persons with obsessive-compulsive 
disorder in Denmark. JAMA Psychiatry, 73(3), 268. 
doi:10.1001/jamapsychiatry.2015.3105 
Mental Illness (n.d.). National institute of mental health. Retrieved October 23, 
2019, from https://www.nimh.nih.gov/health/statistics/mental-illness.shtml. 
Mental Health by the Numbers (2019). Retrieved October 23, 2019, from 
https://www.nami.org/learn-more/mental-health-by-the-numbers. 
Obsessive Compulsive Disorder (n.d.). National institute of mental health. 
Retrieved from https://www.nimh.nih.gov/health/topics/obsessive-
compulsive-disorder-ocd/index.shtml 
Perlis, R. H., Mehta, R., Edwards, A. M., Tiwari, A., & Imbens, G. W. (2018). 
Pharmacogenetic testing among patients with mood and anxiety disorders 
is associated with decreased utilization and cost: A propensity-score 
matched study. Depression and Anxiety, 35(10), 946-952. 
doi:10.1002/da.22742 
PubChem (n.d.). SLC6A4 –solute carrier family 6 member 4 (human). Retrieved 
from https://pubchem.ncbi.nlm.nih.gov/target/gene/SLC6A4/human 
SelfDecode(n.d.). COMT. Retrieved from 
https://www.selfdecode.com/gene/comt/#gene-disease-interactions 
Sina, M., Ahmadiani, A., Asadi, S., & Shams, J. (2018). Association of serotonin  
receptor 2A haplotypes with obsessive compulsive disorder and its 
treatment response in Iranian patients: A genetic and pharmacogenetic 
Running Head: EFFECTS OF GENETIC TESTING 18 
 
study. Neuropsychiatric Disease and Treatment, Volume 14, 1199-1209. 
doi:10.2147/ndt.s163946 
Smits, K. M., Smits, L. J., Schouten, J. S., Peeters, F. P., & Prins, M. H. (2007). 
Does pretreatment testing for serotonin transporter polymorphisms lead to 
earlier effects of drug treatment in patients with major depression? A 
decision-analytic model. Clinical Therapeutics, 29(4), 691-702. 
doi:10.1016/j.clinthera.2007.04.018 
Smoller, J. W. (2015). The genetics of stress-related disorders: Ptsd, depression, 
and anxiety disorders. Neuropsychopharmacology, 41(1), 297-319. 
doi:10.1038/npp.2015.266 
Solomon, H. V., Cates, K. W., & Li, K. J. (2019). Does obtaining cyp2d6 and 
cyp2c19 pharmacogenetic testing predict antidepressant response or 
adverse drug reactions? Psychiatry Research, 271, 604-613. 
doi:10.1016/j.psychres.2018.12.053 
Song, M., Mathews, C. A., Stewart, S. E., Shmelkov, S. V., Mezey, J. G., 
Rodriguez-Flores, J. L., . . . Glatt, C. E. (2017). Rare SYNAPTOGENESIS-
IMPAIRING mutations in slitrk5 are associated with obsessive compulsive 
disorder. Plos One, 12(1). doi:10.1371/journal.pone.0169994 
Terbeck, S., Akkus, F., Chesterman, L. P., & Hasler, G. (2015). The role of 
metabotropic glutamate receptor 5 in the pathogenesis of mood disorders 
and addiction: combining preclinical evidence with human Positron 
Emission Tomography (PET) studies. Frontiers in neuroscience, 9, 86. 
doi:10.3389/fnins.2015.00086 
Running Head: EFFECTS OF GENETIC TESTING 19 
 
Tiwari, A., Zai, C., Zai, G., Cheema, S., Braganza, N., Mueller, D., . . . Kennedy, 
J. L. (2019). Combinatorial pharmacogenomic testing improves 
generalized anxiety disorder treatment response and decreases 
benzodiazapine use. European Neuropsychopharmacology, 29. 
doi:10.1016/j.euroneuro.2017.08.272 
Tomasi, J., Lisoway, A. J., Zai, C. C., Harripaul, R., Müller, D. J., Zai, G. C., . . . 
Tiwari, A. K. (2019). Towards precision medicine in generalized anxiety 
disorder: Review of genetics and pharmaco(epi)genetics. Journal of 
Psychiatric Research, 119, 33-47. doi:10.1016/j.jpsychires.2019.09.002 
Umehara, H., Numata, S., Tajima, A., Nishi, A., Nakataki, M., Imoto, I., . . . 
Ohmori, T. (2016). Calcium signaling pathway is associated with the long-
term clinical response to selective serotonin reuptake inhibitors (ssri) and 
ssri with antipsychotics in patients with obsessive-compulsive disorder. 
Plos One, 11(6). doi:10.1371/journal.pone.0157232 
What is the cost of genetic testing, and how long does it take to get the results? - 








Running Head: EFFECTS OF GENETIC TESTING 20 
 
Table 1. 
Frequency Table for Nominal Variables 
Variable n % 
Age     
    18-24 5 33.33 
    25-34 5 33.33 
    35-44 3 20.00 
    45-54 1 6.67 
    55-60 1 6.67 
Sex     
    female 15 100.00 
Genetic Testing     
    yes 6 40.00 
    no 9 60.00 
Grik1     
    C/A 3 50.00 
    C/C 2 33.33 
    A/A 1 16.67 
ANK3     
    C/C 6 100.00 
CACNA1c     
    A/A 1 16.67 
    G/G 5 83.33 
SL64A     
    La/La 2 33.33 
    L/S 4 66.67 
COMT     
    Met/Met 2 33.33 
    Met/Val 4 66.67 
   











Table 2.  
 


















Variable F p  % M SD n  % M SD n 
             
Number of Med 
Changes 1.62 0.226 
 
 1.83 1.94 6 
 
 3.44 2.65 9 
             
Tolerability 0 1    0.52 6    0.5 9 
yes    33.33     66.67    
no    66.67     33.33    
   
 
    
 
    
Therapeutic Response 1.56 0.234    0.52 6    0.5 9 
none    0     11.11    
sub    66.67     77.78    
therapeutic     33.33     0    
   
 
    
 
    
Side Effects 0.24 0.635    1.26 6    1.32 9 
none    66.67     77.78    
sleep    16.67     11.11    
weight    16.67     0    
mood    0     0    
headaches    0     11.11    
GI    0     0    



















Variable F p  % M SD n  % M SD n 
             
Number of Med 
Changes 0.01 .909 
 
 1.67 2.25 6 
 
 1.78 1.48 9 
             
Tolerability 1.56 .234    .41 6    0.00 9 
yes    83.33     100.00    
no    16.67     0    
   
 
    
 
    
Therapeutic Response 0.04 .847   .55 0.52 6    .53 9 
none    0     0    
sub    50.00     44.44    
therapeutic    50.00     55.56    
   
 
    
 
    
Side Effects 0.01 .939    .55 6    1.67 9 
none    50.00     88.89    
sleep    50.00     0    
weight    0     0    
mood    0     0    
headaches    0     0    
GI    0     11.11    
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Table 4. 
Analysis of Variance Table for change over time for PHQ9 from initial to 6 
months by genetic testing 
Term SS df F p ηp2 
Genetic testing 7.51 1 0.13 .720 0.01 





Running Head: EFFECTS OF GENETIC TESTING 25 
 
Table 5. 
Mean, Standard Deviation, and Sample Size for change over time by genetic 
testing 
Combination M SD n 
Yes -8.33 9.22 6 
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3 months                          6 months
Medication changes at 3 and 6 months
genetically tested
non-tested
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Appendix A 
Data Collection Tool 
 
 
